Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd. on December 13, 2021. The Company is a foreign private issuer organized under the laws of Israel. The filing reports a specific corporate event regarding the expansion of a clinical trial rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event-based disclosure and does not contain financial statements or performance metrics.
Material Changes
On December 13, 2021, the Company announced that Greece's National Organization of Medicines authorized the expansion of its Phase IIb trial for AllocetraTM. The trial evaluates the treatment in severe and critical COVID-19 patients with acute respiratory distress syndrome. The expansion includes adding new sites within Greece.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the context of the clinical trial expansion. No unusual items were reported in this specific document.
Investor Verification Checklist
- Verify the specific number and locations of the new trial sites added in Greece.
- Review the full text of the press release (Exhibit 99.1) for details on patient enrollment targets.
- Check subsequent filings for updates on the Phase IIb trial data readout timeline.
- Confirm the regulatory status of AllocetraTM in other jurisdictions.